Intervention

Memantine

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 55 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials55

Recruiting4

Common conditions25

Lead sponsors shown15

Clinical trials

55 shown

Synaptic Mechanisms of Continuous Theta Burst Stimulation in DepressionNCT07560878 · 2026-03-11

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast CancerNCT06727773 · 2025-08-19

Effect of Acetylcholinesterase Inhibitors on Bone MetabolismNCT06041789 · 2025-02-03

Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First PsychosisNCT04789915 · 2021-05-26

Escalating Doses of Memantine in Down Syndrome (MEDS-123)NCT07531940 · 2026-10-14

NOT_YET_RECRUITING

Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's DiseaseNCT07417670 · 2024-10-04

Efficacy of Chinese Traditional Medicine "Smart Soup" in Cognition and Behavior Regulation in Alzheimer's DiseaseNCT05538507 · 2022-06-01

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryNCT04588246 · 2021-08-05

Memantine Augmentation of Targeted Cognitive Training in SchizophreniaNCT04857983 · 2021-07-06

Monitoring Anti-Dementia Drugs by Serum LevelsNCT04117178 · 2020-02-04

Memantine for Prevention of Cognitive Decline in Patients With Breast CancerNCT04033419 · 2019-09-25

Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineNCT03858270 · 2019-04-01

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's DiseaseNCT03703856 · 2019-01-31

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's DiseaseNCT03316898 · 2018-09-30

Memantine Effects on Sensorimotor Gating and Neurocognition in SchizophreniaNCT03860597 · 2018-04-01

Prediction of Cognitive Properties of Memantine for Neurodegenerative DiseasesNCT02288000 · 2016-09-14

The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's DiseaseNCT05102045 · 2016-09-01

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a StudyNCT02580305 · 2015-09-01

Treatment of Pendular Nystagmus in OPTNCT02466191 · 2015-06-01

Pharmacovigilance in Gerontopsychiatric PatientsNCT02374567 · 2015-01-01

Biomarker Strategies for Medication-Enhanced Cognitive Training in SchizophreniaNCT01555697 · 2014-07-01

Effect of Memantine on ERP in Early Schizophrenia and Healthy SubjectsNCT02233556 · 2014-02-01

Memantine add-on for Cognitive and Negative Symptoms of SchizophreniaNCT02001103 · 2014-01-01

Brain Aging and Treatment Response in Geriatric DepressionNCT01902004 · 2013-10-01

Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple SclerosisNCT01744444 · 2012-11-01

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease TherapyNCT01677754 · 2012-10-24

Alzheimer's Disease - Input of Vitamin D With mEmantine AssayNCT01409694 · 2011-09-01

Treatment Resistant Geriatric Depression in Primary CareNCT01392287 · 2010-05-01

Memantine and Antipsychotics UseNCT00649220 · 2008-07-01

Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's DiseaseNCT00800709 · 2008-07-01

Memantine on Aggression and Agitation of Alzheimer's Disease (AD)NCT00703430 · 2008-03-01

Donepezil and Memantine in Moderate to Severe Alzheimer's DiseaseNCT00866060 · 2008-02-01

Memantine Therapy for Multiple SclerosisNCT00638833 · 2007-09-01

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's DiseaseNCT00235716 · 2007-08-01

Memantine Versus Donepezil in Early Stages of Alzheimer's DiseaseNCT00505167 · 2007-07-01

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's DiseaseNCT00476008 · 2007-07-01

Effect of Memantine on Functional Communication in Patients With Alzheimer's DiseaseNCT00469456 · 2007-04-01

Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy BodiesNCT00855686 · 2007-01-01

Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver TrainingNCT00120874 · 2006-08-01

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and DementiaNCT00294554 · 2006-04-01

Namenda (Memantine) for Non-motor Symptoms in Parkinson's DiseaseNCT00646204 · 2006-04-01

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive ImpairmentNCT01876823 · 2006-04-01

Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)NCT00630500 · 2006-02-01

Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute SchizophreniaNCT00148590 · 2005-11-01

Study on Cognitive Disorders of Multiple SclerosisNCT01074619 · 2005-09-01

A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's DiseaseNCT00862940 · 2005-09-01

Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older AdultsNCT00183729 · 2005-08-01

The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease PatientsNCT00255086 · 2005-05-01

The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's DiseaseNCT01921972 · 2004-11-01

Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's DiseaseNCT00857233 · 2004-06-01

Trial of Memantine for Cognitive Impairment in Multiple SclerosisNCT00300716 · 2004-04-01

Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic SchizophreniaNCT00148616 · 2004-04-01

Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's DiseaseNCT00857649 · 2003-12-01

A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)NCT00000867 · 1996-12-01

A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy AdultsNCT02001584

Common conditions

Leading sponsors

H. Lundbeck A/S4 University of California, San Diego4 Hospices Civils de Lyon2 M. Schaefer, MD2 Mclean Hospital2 National Taiwan University Hospital2 UNC Lineberger Comprehensive Cancer Center2 Allergan1 Baylor College of Medicine1 Bjorn H. Ebdrup1 Carnot Laboratories1 Charite University, Berlin, Germany1 Clinica Universidad de Navarra, Universidad de Navarra1 Duke University1 Eric Lenze1

Trial status mix

COMPLETED34

TERMINATED9

UNKNOWN6

RECRUITING4

NOT_YET_RECRUITING1

WITHDRAWN1

Phase mix

PHASE418

PHASE315

PHASE214

PHASE17

NA4

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.